Review papers with raw data transparency

Visual summary — Key claims (with targeted citations)

• Claim A: The OM LPS/LOS layer is the primary diffusion barrier for hydrophobic molecules and is actively remodeled to tune permeability and resist cationic peptides — supported by biochemical and genetic work discussed in the review. Maher & Hassan LPS role summary PEZ LPS transport review
• Claim B: Porins—structure (L3 constriction), electrostatics, and dynamics—critically shape entry for many polar antibiotics; species differences in porin repertoires explain major cross‑species variation. Porins structural review
• Claim C: RND tripartite efflux pumps act synergistically with OM selectivity to prevent intracellular accumulation; removing OM or efflux reveals the orthogonal filtering properties of each barrier. Maher & Hassan efflux/OM interplay Krishnamoorthy et al. hyperporination
• Claim D (Applied): Physicochemical rules (eNTRy, low MW, polarity, primary amines) help design Gram‑negative active molecules but are not universal—E. coli bias and species variation limit transferability. Maher & Hassan eNTRy discussion eNTRy / accumulation rules success

Critical appraisal (concise, evidence‑based)

1. Strengths
   • Thorough synthesis of modern tools: TraDIS, hyperporination, OM/efflux deficient strains, kinetic models—correctly framed as the methods now enabling mechanistic decomposition of permeability Maher & Hassan methods summary.
   • Balanced incorporation of medicinal chemistry (eNTRy) with biophysics—useful for readers bridging disciplines.
2. Limitations and blind spots (important)
   • Over‑dependence on E. coli–centric datasets. The review acknowledges this, but the field still lacks standardized cross‑species accumulation datasets—so the extrapolations to non‑model pathogens remain speculative Maher & Hassan E. coli bias.
   • Quantitative link between whole‑cell accumulation and MIC/efficacy remains imperfect; the review reports models (bifurcation kinetics) but notes that accumulation ≠ potency due to downstream effects and exposure timing Maher & Hassan kinetics note.
   • LPS modification functional trade‑offs (resistance vs fitness) are presented correctly but mechanistic causality for many modifications (which ones change porin organization, fluidity, efflux induction) is still sparse; the review correctly calls this a research gap.
3. Interpretation cautions the authors could emphasize more
   • Assay dependence: accumulation readouts (mass spec, CHAMP, fluorescence) and growth-phase/economic conditions change results; the review mentions growth-phase effects but users should treat accumulation/efflux readouts as context‑dependent Maher & Hassan growth-phase caveat Growth rate affects accumulation.

Concrete experimental gaps & high‑value next steps (actionable)

• Assemble standardized, multi‑species accumulation datasets using CHAMP or click‑chemistry probes plus mass spec across: E. coli, K. pneumoniae, P. aeruginosa, A. baumannii, and clinical isolates—test identical small‑molecule panels under matched growth conditions to derive cross‑species permeability matrices Maher & Hassan data gap CHAMP accumulation method.
• Systematically pair hyperporination/efflux knockout backgrounds with MD and porin scoring models to map which chemotypes are porin‑ versus lipid‑mediated in each species (generate species maps of 'in' vs 'out' filtering properties).
• Perform longitudinal in vivo pharmacokinetic→bacterial accumulation→efficacy experiments (e.g., neutropenic thigh model) to test kinetic model predictions linking barrier constants to MIC and treatment outcomes—this directly addresses the review's noted model‑to‑clinic gap.

Short, evidence‑tagged recommended reading (selected)

1. Maher & Hassan (mBio)
2. Acosta‑Gutiérrez et al. (Nat Rev Microbiol)
3. Richter et al. (Nature)

Conclusions (brief)

Maher & Hassan provide a tight, up‑to‑date minireview that accurately frames the Gram‑negative permeability barrier as a systems problem (OM/LPS + porins + efflux + IM transport), highlights promising design strategies (eNTRy modifications; Trojan‑horse siderophores), and correctly warns that no universal rule fits all species. Its main limitations reflect the underlying literature: E. coli bias and uneven cross‑species quantitative data. The paper is a useful roadmap; the field now needs standardized, multi‑species accumulation datasets and coordinated in vivo validation studies to turn guidelines into robust, generalizable rules. Maher & Hassan wrap-up